Fig. 1

Downregulation of PRDM16 correlates with poor prognosis of lung adenocarcinoma patients. a and b, Transcriptional level of PRDM16 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LSCC) compared to that in normal lung tissues. Data were obtained from the UALCAN database [35]. c, Immunoblotting analysis of PRDM16 expression in lung cancer and matched normal lung tissues (magnification: × 200). β-actin was quantified as an internal control. d, Immunohistochemistry staining of PRDM16 in lung cancer and normal lung tissues. e and f, Correlation scatter plot of the PRDM16 mRNA expression and methylation levels in lung adenocarcinoma and lung squamous cell carcinoma. Data were obtained from the cBioPortal database [36, 37]. g and h, Kaplan-Meier plots of overall survival of patients with lung adenocarcinoma and lung squamous cell carcinoma stratified by PRDM16 expression. Data were obtained from the Kaplan-Meier plotter database [38]. i and j, Percentage of lung adenocarcinoma patients with high expression and low expression of PRDM16 stratified according to lymph node status or TNM stage (n = 497)